Eutropics gets NCI contract to develop Leukemia treatment

Wed, 09/19/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Cambridge-based Eutropics Pharmaceuticals signed a deal with the National Cancer Institute to develop its diagnostic assay for cancer treatments in patients with Acute Myelogenous Leukemia, (AML).

Through the Institute’s Small Business Initiative Research (SBIR) initative, a program designed to develop and commercialize technologies and products to prevent, diagnose, and treat cancer, the partnership enables further development of Eutropics’ proprietary BH3 profiling diagnostic assay for personalized medicine approaches in patient management of AML, a cancer of the blood and bone.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.